
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics Inc's stock outlook remains favorable due to the recent FDA approval to lower the age eligibility for the Phase 3 HERO trial of its leading product candidate, ARD-101, expanding the patient population it can treat for hyperphagia associated with Prader-Willi Syndrome (PWS). The company is also strategically addressing the robust market for obesity treatments by developing oral therapeutics that could complement existing injectable therapies, positioning itself well within a competitive landscape. While the likelihood of success for ARD-101 has been adjusted to 50% and its potential launch delayed to 2029, the ongoing advancements and trial progress suggest strong underlying growth potential for Aardvark Therapeutics in the future.
Bears say
Aardvark Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily related to delays and uncertainties surrounding its Phase 3 clinical trial for ARD-101. Key risks include the potential for negative clinical results, regulatory hurdles that could prolong the approval process, and the possibility of unanticipated safety issues emerging, which collectively threaten the success of its flagship product targeting hyperphagia associated with Prader-Willi Syndrome (PWS). Additionally, the company has suspended guidance for the third-quarter HERO trial topline data, casting further doubt on its ability to meet key developmental milestones and maintain investor confidence.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares